Archive Category: Green Zone Fortunes Updates

For our monthly portfolio review video, I cover what’s working well and what I’m keeping an eye on for several of our stocks. Note: I don’t cover every position this month. If you have a question about a stock that I don’t answer in this update, you can write to my team and me anytime.

This week, I discuss the stock that Adam O’Dell and I chose for the May issue of Green Zone Fortunes: Supernus Pharmaceuticals (Nasdaq: SUPN). With its new, disruptive ADHD prescription, Qelbree, we’re convinced that Supernus is a game changer for adults and children alike.

When I learned about the latest medical innovation of the company I’m sharing with you today, I researched the stock and saw how it stacks up in our Green Zone Ratings system. It was clear that I needed to share it with you, my Green Zone Fortunes readers. I told my co-editor Charles Sizemore and my team that I had to write this issue. I was that pumped to tell you about this stock.

Today, we’re talking all about our Imperium DNA powerhouse, Twist Bioscience (Nasdaq: TWST). First, congratulations to the folks who got into from the beginning. I recommended this company in the May 2020 issue of Green Zone Fortunes. You’ve already had the chance to lock in partial profits of up to 100% on part of your position.

I’ve been saying that our “Imperium” stock, Twist Bioscience Corp. (Nasdaq: TWST), has the potential to be a $1,000 stock, and that hasn’t changed.